The study by Treggiari et al1 published in this issue of the Archives of Pediatrics & Adolescent Medicine represents the latest paradigm shift in the antimicrobial management of people with cystic fibrosis (CF). It is worthwhile to reflect on the sea changes that have occurred in the antimicrobial management of patients with CF during the past 3 decades. During the 1970s and 1980s, clinicians questioned the need for antimicrobial therapy during a pulmonary exacerbation. To assess this, a placebo-controlled trial was conducted in which patients having an exacerbation were randomized to antibiotics vs placebo.2 There was a death in the placebo group. Investigators then asked if clinical improvement during CF exacerbations was the result of antibiotics or the result of the supportive care (eg, rest, bronchodilators, more effective chest physiotherapy) that patients received while hospitalized. To address this question, patients having an exacerbation were hospitalized and randomized to initiation of antibiotics on admission vs 4 days of supportive care prior to the initiation of antibiotics.3 Patients receiving antibiotics on admission did better. The next paradigm shift for the use of antimicrobials in CF occurred when tobramycin inhalation solution was introduced for long-term suppressive therapy in patients chronically infected with Pseudomonas aeruginosa, in efforts to slow the deterioration of lung function.4 While management of exacerbations and long-term suppressive therapy are currently the standard of care for CF, neither of these strategies addresses prevention of disease progression. Thus, the CF community has increasingly practiced early treatment (aka, eradication) of P aeruginosa, ie, initiation of antimicrobial treatment in response to a positive culture for this microorganism, regardless of signs and symptoms of infection. However, the optimal strategy for early treatment and its safety and efficacy were largely unknown and required additional study.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Clubbing can occur in a variety of illnesses. It should be considered among patients with cystic...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.